Previous 10 | Next 10 |
President Trump signs the STOP Act today, sweeping bipartisan legislation aimed at addressing the opioid crisis. More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news, Read more ...
Gritstone Oncology (NASDAQ: GRTS ) initiated with Buy rating and $26 (71% upside) price target at BTIG Research. Initiated with Overweight rating and $25 price target at Barclays. Initiated with Outperform rating at Cowen and Company. More news on: Gritstone Oncology, AcelRx Pharmaceutical...
ADAP -34% on disappointing SPEAR cell data. More news on: Adaptimmune Therapeutics plc, Aduro Biotech, Mirati Therapeutics, Inc., Stocks on the move, Top stock market news, , Read more ...
REDWOOD CITY, Calif. , Oct. 19, 2018 /PRNewswire/ -- In response to opinions expressed following the U.S. Food and Drug Administration (FDA) Anesthetic and Analgesic Drug Products Advisory Committee meeting on October 12 , AcelRx Pharmaceuticals, Inc. (AcelRx) (Nasdaq: ACRX) stands ...
Last Friday, exactly one year after previously receiving a CRL from the FDA, AcelRx Pharmaceuticals' ( ACRX ) lead drug candidate Dsuvia received a 10-3 vote from an FDA Advisory Committee - according to the Advisory Committee, the benefits of approving Dsuvia for use in a medically supervis...
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Roche Enacts Deal With Ionis For Dry AMD Drug News: Recently, Roche ( RHHBY ) announced that it had formed a deal with Ionis Pharmaceuticals ( IONS )...
NEW YORK, Oct. 17, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of CURO Group Holdings Corp. (NYSE:CURO), BiondVax Pharmaceuticals Ltd. (NAS...
Abiword HTML Document Source AcelRx Pharmaceuticals' ( ACRX ) DSUVIA (sufentanil sublingual tablet) went under intense scrutiny by the FDA’s Anesthetic and Analgesic Drug Products Advisory Committee (adcom) on Friday. After a long day of presentations and debate, the commit...
REDWOOD CITY, Calif. , Oct. 15, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in a medically supervised setting, today announced a poster ...
ACRX +21% on positive Ad Com vote for Dsuvia and positive analyst action . More news on: AcelRx Pharmaceuticals, Inc., Cambium Learning Group, Inc., SELLAS Life Sciences Group, Inc., Stocks on the move, , Top stock market news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
AcelRx Pharmaceuticals Inc. Company Name:
ACRX Stock Symbol:
NASDAQ Market:
AcelRx Pharmaceuticals Inc. Website:
AcelRx Announces Rebranding With Name Change to Talphera, Inc. PR Newswire Name change to "Talphera" reflects a new era of the Company in partnership with the medical community developing novel solutions for medically supervised settings Talphera will begin trading on ...
AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States PR Newswire Use of CRRT increased during COVID and remained at these higher utilization levels Study results demonst...
AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update PR Newswire Niyad™ Investigational Device Exemption (IDE) approval by the FDA achieved in third quarter Company plans to begin its Niyad registrational study this quarter with topl...